Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $52.04 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $52.04.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $60.63.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $80.97.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $78.21.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $52.04 10-Q · filed 2026-08-06 |
| 2026-03-31 | $60.63 10-Q · filed 2026-05-12 |
| 2025-12-31 | $80.97 10-K · filed 2026-03-09 |
| 2025-09-30 | $78.21 10-Q · filed 2025-11-12 |
| 2025-06-30 | $81.87 10-Q · filed 2025-08-05 |
| 2025-03-31 | $87.26 10-Q · filed 2025-05-06 |
| 2024-12-31 | $98.87 10-K · filed 2025-03-11 |
| 2024-09-30 | $103.21 10-Q · filed 2024-11-07 |
| 2024-06-30 | $106.89 10-Q · filed 2024-08-06 |
| 2024-03-31 | $93.95 10-Q · filed 2024-05-07 |
| 2023-12-31 | $100.13 10-K · filed 2024-03-12 |
| 2023-09-30 | $103.74 10-Q · filed 2023-11-07 |
| 2023-06-30 | $106.91 10-Q · filed 2023-08-08 |
| 2023-03-31 | $113.92 10-Q · filed 2023-05-09 |
| 2022-12-31 | $125.97 10-K · filed 2023-03-07 |
| 2022-09-30 | $4.33 10-Q · filed 2022-11-08 |
| 2022-06-30 | $4.48 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.57 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.87 10-K · filed 2022-03-08 |
| 2021-09-30 | $5.19 10-Q · filed 2021-11-12 |
| 2021-06-30 | $5.23 10-Q · filed 2021-08-12 |
| 2021-03-31 | $5.16 10-Q · filed 2021-05-13 |
| 2020-12-31 | $4.86 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |